Filing Flows › Citius Oncology (CTOR) › Q3 FY26 › vs Q2 FY26
Citius Oncology (CTOR) Q3 FY26 vs Q2 FY26 (quarter over quarter)
Citius Oncology's revenue fell $174K (-10%) from $1.7M in Q2 FY26 to $1.5M in Q3 FY26.
Citius Oncology, Q3 FY26: revenue $1.5M, operating margin -583.5%, net loss $8.9M, operating cash flow −$2.7M. The chart draws each line against Q2 FY26, the increases inside each band.
Every line
| Line | Q3 FY26 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $1.5M | $1.7M | −$174K | -10% |
| Income tax benefit | $107K | $231K | −$124K | -54% |
| Net loss | $8.9M | $26.6M | −$17.7M | -66% |
| Costs & expenses | $10.5M | $30.3M | −$19.8M | -65% |
| Operating costs | $10.2M | $30.3M | −$20.1M | -66% |
| Interest & other, net | $314K | −$1.8M | $2.1M | — |
| Cost of revenue | $492K | $329K | $163K | +50% |
| Research & development | $218K | $1.1M | −$861K | -80% |
| General & admin | $4.2M | $23.6M | −$19.4M | -82% |
| Other operating costs | $5.3M | $5.2M | $34K | +0.6% |
| Operating cash sources | $8.9M | $26.6M | −$17.7M | -66% |
| Share-based compensation | $3.6M | $3.5M | $34K | +1% |
| Working capital & other | $2.7M | $19.3M | −$16.6M | -86% |
| Cash used in operations | $2.7M | $3.8M | −$1.1M | -29% |
| Net loss absorbed | $8.9M | $26.6M | −$17.7M | -66% |
Questions
How much did Citius Oncology's revenue grow quarter over quarter in Q3 FY26?
Citius Oncology's revenue fell $174K (-10%) from $1.7M in Q2 FY26 to $1.5M in Q3 FY26.